Eitr Biologics' ODIN platform produces ultra‑small, single‑domain bispecific antibodies that can penetrate solid tumors, gram‑negative bacterial defenses, and deep viral reservoirs. The nanometer‑scale format enables rapid, high‑potency immune engagement with lower manufacturing costs, offering a streamlined path for pharma and biotech immunotherapy development.
Funding
Funding not disclosed
Founders
Product
Problem
Conventional antibody therapeutics are large, costly, and often unable to penetrate solid tumors, gram‑negative bacterial defenses, or deep viral reservoirs, limiting their efficacy in oncology, antibacterial, and antiviral treatments.
Solution
Eitr Biologics’ Orthogonal Dual‑Interacting Nanotherapeutic (ODIN) platform creates ultra‑small single‑domain antibody molecules that are engineered for rapid, high‑potency immune engagement. The reduced size enables deeper tissue penetration and tighter immune synapse formation, improving target access in solid tumors, across the lipopolysaccharide layer of gram‑negative bacteria, and within hard‑to‑reach viral niches. By leveraging a single‑domain bispecific design, ODIN therapeutics aim to deliver faster therapeutic action at lower manufacturing cost compared with traditional IgG antibodies. The platform supports rapid development pipelines for immunotherapies across oncology, antibacterial, and antiviral indications.
Target Audience
Primary customers are pharmaceutical and biotech companies developing immunotherapies for solid‑tumor oncology, gram‑negative bacterial infections, and persistent viral diseases.
Features
- Single‑domain bispecific antibodies with nanometer-scale dimensions for enhanced tissue diffusion
- Orthogonal dual‑interacting architecture that simultaneously engages target antigens and immune effector cells
- Engineered to traverse gram‑negative bacterial LPS barriers, opening new antibacterial target spaces
- Designed to reach deep organ and tissue viral reservoirs inaccessible to conventional IgGs
- Streamlined production process yielding lower manufacturing costs and faster development timelines